Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users

HIV Infections Clinical Trial

Official title:

A Phase III Randomized Controlled Trial to Evaluate the Efficacy of Drug Treatment in Prevention of HIV Infection and Death Among Opiate Dependent Injectors

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00270257
• Other study ID #: HPTN 058
• Secondary ID: 10144
• Status: Terminated
• Phase: Phase 3
• Start date: May 2008
• Est. completion date: July 2012

Study information

• Verified date: December 2016
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Drug abuse and HIV/AIDS are serious global health problems. Injection drug use is currently the major mode of transmission of HIV in many countries. The purpose of this study is to determine the effectiveness of drug and risk reduction counseling combined with either substitution drug treatment with buprenorphine/naloxone (BUP/NX) or short-term detoxification with BUP/NX in preventing HIV transmission among injection drug users. Participants will be recruited for this study in China and Thailand.

Description:

Effective HIV prevention among injection drug users (IDUs) requires educating the at-risk population about HIV transmission and risky behavior, and providing the means for behavior change. Current treatment for opiate dependence focuses on reducing the frequency of drug use. BUP/NX is a combination pill currently used to treat opiate-dependent individuals. This trial will evaluate the effectiveness of two therapies in preventing HIV transmission among IDUs. Drug and risk reduction counseling combined with either long term medication assisted treatment (LT-MAT) with BUP/NX or short term medication assisted treatment (ST-MAT) with BUP/NX will be compared in preventing the transmission of HIV among opiate-dependent individuals. This study will last 4.5 years. Participants in this study will be randomly assigned to one of two treatment arms. Group 1 will receive LT-MAT with BUP/NX. Group 2 will receive ST-MAT with BUP/NX. An initial 4-week safety and feasibility phase will involve the first 50 participants at each site and will last approximately 30 weeks. Study visits will occur every week and will include a physical exam and blood and urine collection. The main treatment phase of the study will last 52 weeks. Participants in Group 1 will receive BUP/NX under the tongue, at first daily and then three times a week for 52 weeks. Participants assigned to Group 1 will take part in a BUP/NX reduction phase, which will occur between Weeks 47 and 52. Participants in Group 2 will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator. Participants assigned to Group 2 will receive BUP/NX for a maximum of 18 days; detoxification may be repeated at Week 26 if the participant is still injecting opiates. After Week 4 of the safety phase and Weeks 26 and 52 of the overall study, participants will complete an intervention acceptability assessment. In addition, participants in both groups will attend drug and risk reduction counseling weekly. After the first 12 weeks, participants will return every 4 weeks for 10 more counseling sessions. HIV testing, hepatitis C testing, risk assessment, and urine tests for opiates will occur at screening and at Weeks 26, 52, 78, 104, 130 and 156. Plasma from blood samples will be stored at each of these visits. Hepatitis B testing will occur at Week 26. Participants in China will attend study visits through approximately Week 104, and participants in Thailand will attend study visits through approximately Week 156. Participants in China who have been incarcerated may participate in an optional substudy, which is examining the withdrawal effects from BUP/NX after incarceration. Participants who agree to take part in the substudy will attend one study visit and will complete a questionnaire.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1251
• Est. completion date: July 2012
• Est. primary completion date: July 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• HIV-uninfected within 28 days of enrollment
• Meets DSM-IV criteria for opiate dependence
• Positive urine test for opiates
• Injected opiates at least 12 times in the 28 days prior to enrollment, according to self-report
• Willing to use acceptable forms of contraception for the first 12 months of the study
• Able to provide contact information and willing to be contacted by study staff as necessary
• Available for study visits for at least 2 years

Exclusion Criteria:

• Current treatment with methadone, morphine, levo-alpha-acetyl-methadol (LAAM), naltrexone, or nalmefene
• Currently enrolled in another HIV prevention or drug use intervention study
• Known sensitivity to buprenorphine or naloxone
• Requires immediate medical attention for dependence on alcohol, benzodiazepines, or other substances. People who are dependent on tobacco are not excluded.
• Currently injecting drugs of abuse other than opiates, more than twice in the last 28 days, according to self-report
• Psychological disturbance or cognitive impairment that may interfere with the study
• Acute or chronic kidney failure
• Certain abnormal laboratory values
• Any other medical or psychiatric condition that, in the opinion of the investigator, would make participation in this study unsafe
• Pregnant or breastfeeding

Inclusion Criteria for Substudy:

• Current or former participant in HPTN 058 study in Xinjiang who was actively in the long-term treatment arm on stable maintenance dose of Suboxone when detained/arrested (last dose within 2 days of incarceration), resulting in immediate cessation of Suboxone without tapering
• Currently released from detention
• Willing to complete one-time questionnaire
• Willing to sign informed consent

Exclusion Criteria for Substudy:

• Any medical or psychiatric condition that, in the opinion of the investigator, would make participation in the study unsafe, or would otherwise interfere with the study objectives or interpretation

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• Communicable Diseases
• HIV Infections
• Infections
• Opioid-Related Disorders

Intervention

Drug:
• Buprenorphine/Naloxone
Oral tablet

Locations

Country	Name	City	State
China	Heng County Ctr. for Disease Control & Prevention CRS	Hengzhou Town	Guangxi
China	Guangxi Ctrs. for Disease Control & Prevention and for HIV/AIDS Prevention & Control CRS	Nanning	Guangxi
China	Xinjiang CRS	Urumqi	Xinjiang
Thailand	CMU HIV Prevention CRS	Chiang Mai

Sponsors (2)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	National Institute on Drug Abuse (NIDA)

Countries where clinical trial is conducted

China,  Thailand, 

References & Publications (5)

Aceijas C, Stimson GV, Hickman M, Rhodes T; United Nations Reference Group on HIV/AIDS Prevention and Care among IDU in Developing and Transitional Countries. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS. 2004 Nov 19;18(17):2295-303. — View Citation

Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004145. Review. Update in: Cochrane Database Syst Rev. 2008;(2):CD004145. — View Citation

Koester S, Glanz J, Barón A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav. 2005 Mar;9(1):27-39. — View Citation

Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother. 2002 Feb;36(2):312-21. Review. — View Citation

Ruan Y, Qin G, Liu S, Qian H, Zhang L, Zhou F, He Y, Chen K, Yin L, Chen X, Hao Q, Xing H, Song Y, Wang Y, Hong K, Chen J, Shao Y. HIV incidence and factors contributed to retention in a 12-month follow-up study of injection drug users in Sichuan Province, China. J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):459-63. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evidence of HIV-1 Infection or Death for Visits up to 104 Weeks	The primary endpoint for the study was cumulative HIV infection or death after a second year of follow-up (i.e. at week 104), one year after completion of the treatment phase, designed to test a durable intervention effect.	For visits up to week 104
Secondary	Number of Participants With Urinalysis Results Positive for Opiates	Urine drug screen were assessed monthly and semiannually.	Measured through Week 104
Secondary	Self-report of Continued Injection Opiate Use in the Last 30 Days	All participants completed interviewer-administered assessments of injection and non-injection drug use at baseline and at semi-annual visits.	Measured through Week 104
Secondary	Number of Participants Reported Using Injection Equipment (Needles, Syringes, Cookers, Cottons, and Rinse Water) in the Prior 6 Months		Measured through Week 104
Secondary	Self-reported Number of Injections in the Last Month		Measured through Week 104
Secondary	Incident Hepatitis C Infections for Thailand and China	HCV antibody using two different HCV EIA assays (Ortho HCV antibody version 3.0 and Wantai HCV antibody assay) at baseline and between 26-156 weeks later.; If both HCV EIA antibody assays were nonreactive, then the participant was considered not to be HCV infected. If either assay was reactive, then the Ortho HCV assay was repeated in duplicate. If two of 3 Ortho HCV assays were reactive, then the participant was considered to be HCV infected. Samples that were repeatedly reactive for HCV antibody at a follow-up visit were tested for HCV RNA by the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV assay. Not all participants had follow-up testing performed in China due to early closure of the study by the Data Safety Monitoring Board on account of futility due to a low HIV incidence (the primary study endpoint).; Analysis was done separately for both countries	Measured through week 156 in Thailand and 104 weeks in China
Secondary	Incident Hepatitis B Infections	Serum samples were tested at baseline and between 26-52 weeks later for Hepatitis B surface antigen (HBsAg) using a commercial enzyme immunoassay (EIA) (Abbott Murex HBsAg version 3.0). If the HBsAg test was initially non-reactive, then the participant was considered to be negative for HBsAg. If the HBsAg test was initially reactive, then it was repeated in duplicate. If at least two of 3 tests were reactive, then the participant was considered to be positive for HBsAg.	Measured through week 52

External Links

•   Click here for more information about understanding HIV prevention
•   Haga clic aquí para ver información sobre este ensayo clínico en español.